Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 10, 2025Journal of Thrombosis and ThrombolysisOpen Access

Long-term efficacy and safety of direct oral anticoagulants in venous thrombotic antiphospholipid syndrome patients not candidate to warfarin: A pilot prospective case series study

View Full Paper
Ask AI
Bookmark
Share

Authors

DPDaniele PastoriDMDanilo MenichelliGPGian Marco Podda

Discussion

Loading...

Member takes

Overview

Pilot study evaluates safety and efficacy of direct oral anticoagulants in APS patients, suggesting potential benefits.

Key Points

  • No recurrent venous thromboembolism episodes occurred during a mean follow-up of 50.1 months.
  • The incidence rate of bleeding was 5.3 per 100 patient-years, with 2 major bleeding cases reported.
  • Eighteen APS patients unsuitable for warfarin treatment were included in this prospective case series study.
  • Findings suggest that direct oral anticoagulants may be a viable alternative for patients with venous thrombotic APS.

Cite This Study

Pastori et al. (2025) studied this question.

synapsesocial.com/papers/68c243acb210217d647a89d4https://doi.org/10.1007/s11239-025-03158-3
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CO04 | Direct oral anticoagulants in antiphospholipid syndrome: a single center real-life experience2025
  2. 2Evaluating the Efficacy and Safety of Direct Oral Anticoagulants Compared to Vitamin K Antagonists in Patients with Antiphospholipid Syndrome: Updated Systematic Review and Meta-Analysis2025
  3. 3Real-world outcomes of direct oral anticoagulants versus warfarin in patients with single-positive antiphospholipid antibody syndrome: A trinetx cohort analysis2025
  4. 4PO37 | Single centre experience on anticoagulation in carriers of non-mild inherited thrombophilia: direct oral anticoagulants (DOAC) efficacy and safety2025
  5. 5Evaluation of six-month clinical outcomes of patients with venous thromboembolism treated with apixaban, rivaroxaban, edoxaban or dabigatran2026